AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-305-671-0200</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If the information provided is not</u> complete, correct, or legible, the authorization process can be delayed.

Drug Requested: droxidopa (Northera[®])

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name:			
Member AvMed #:	Date of Birth:		
Prescriber Name:	_		
Prescriber Signature:	Date:		
Office Contact Name:			
Phone Number:	Fax Number:		
DEA OR NPI #:			
DRUG INFORMATION: Authorization may be dela	ayed if incomplete.		
Drug Form/Strength:			
Dosing Schedule:			
Diagnosis:	ICD Code, if applicable:		
Weight:	Date:		
CLINICAL CRITERIA: Check below all that apply. support each line checked, all documentation, including lab provided or request may be denied.			
• Prescriber is: 🗆 Specialist	Cardiologist		
1. Does the patient have orthostatic dizziness or lighthe caused by primary autonomic failure (Parkinson Disc failure?	• 1		

□ Yes □ No

2. Does the patient have dopamine beta-hydroxylase deficiency or non-diabetic autonomic neuropathy?

🗆 Yes 🗆 No

(Continued on next page)

3.	es the patient have any cardiac issues such as hypertension, cardiovascular risk factors, or coronary				
	artery disease?		Yes		No
4.	4. Does the patient have any documented history of cardiovascular attacks?		Yes		No
5.	5. Will supine blood pressure be monitored during therapy?		Yes		No
	AND				
•	Patient has tried and failed <u>ALL</u> of the following:				
	□ midodrine <u>AND</u> □ fludrocortisone				

** <u>Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.</u> **

<u>Previous therapies will be verified through pharmacy paid claims or submitted chart notes.</u>

*Approved by Pharmacy and Therapeutics Committee: 9/18/2014; 1/19/2017 REVISED/UPDATED/REFORMATTED: 42/19/2014; 5/22/2015; 42/28/2015; 42/19/2016; 1/1917; 3/28/2017; 8/15/2017;6/19/2019; 10/27/2023;